Table 2.
Chemotherapy in combination with antiangiogenic agents in randomized trials in various malignancies
| References | Tumor type | Regimen (number of patients) | PFS (months) | OS (months) |
|---|---|---|---|---|
| Saltz et al72 | CRC | FOLFOX-4/XELOX + bevacizumab (701) | 9.4 versus 8.0 (HR =0.83; P=0.0023) | 21.3 versus 19.9 (HR =0.89; P=0.0769) |
| FOLFOX-4/XELOX + placebo (699) | ||||
| Giantonio et al73 | FOLFOX-4 + bevacizumab (290) | 7.3 versus 4.7 (HR =0.61; P<0.0001) | 12.9 versus 10.8 (HR =0.75; P=0.0011) | |
| FOLFOX-4 + placebo (289) | ||||
| Van Cutsem et al74 | FOLFIRI + aflibercept (612) | 6.9 versus 4.67 (HR =0.758; P=0.00007) | 13.5 versus 12.06 (HR =0.817; P=0.0032) | |
| FOLFIRI + placebo (614) | ||||
| Tabernero et al75 | FOLFIRI + ramucirumab (536) | 5.7 versus 4.5 (HR =0.793; P<0.0005) | 13.3 versus 11.7 (HR =0.884; P=0.0219) | |
| FOLFIRI + placebo (536) | ||||
| Sandler et al76 | NSCLC | CbP + bevacizumab (434) | 6.2 versus 4.5 (HR =0.66; P<0.001) | 12.3 versus 10.3 (HR =0.79; P=0.003) |
| CbP (444) | ||||
| Reck et al77 | CG + bevacizumab (345) | 6.7 versus 6.5 versus 6.1 | NA | |
| CG + bevacizumab (351) | (HR =0.75; P=0.0026; 7.5 mg) | |||
| CG + placebo (347) | (HR =0.82; P=0.03; 15 mg) | |||
| Barlesi et al78 | Bevacizumab (125) | 3.7 versus 7.4 (HR =0.48; P<0.001) | NA | |
| Bevacizumab + pemetrexed (128) | ||||
| Zhou et al79 | CbP + bevacizumab (138) | 9.6 versus 6.5 (HR =0.40; P<0.001) | 24.3 versus 17.7 (HR =0.68; P=0.0154) | |
| CbP (138) | ||||
| Pujade-Lauraine et al80 | ROC | Paclitaxel + PLD/topotecan + bevacizumab (179) | 6.7 versus 3.4 (HR =0.48; P<0.001) | NS |
| Paclitaxel + PLD/topotecan (182) | ||||
| Aghajanian et al81 | GC + bevacizumab (242) | 12.4 versus 8.4 (HR =0.484; P<0.0001) | NS | |
| GC + placebo (242) | ||||
| Ohtsu et al82 | GC/GEJ | Fluoropyrimidine–cisplatin + bevacizumab (387) | 6.7 versus 5.3 (HR =0.80; P=0.0037) | 12.1 versus 10.1 (HR =0.87; P=0.1002) |
| Fluoropyrimidine–cisplatin + placebo (387) | ||||
| Wilke et al83 | Paclitaxel + ramucirumab (330) | 4.4 versus 2.9 (HR =0.635; P<0.0001) | 9.6 versus 7.4 (HR =0.807; P=0.017) | |
| Paclitaxel + placebo (335) |
Abbreviations: CRC, colorectal cancer; NSCLC, non-small-cell lung cancer; ROC, recurrent ovarian, primary peritoneal, or fallopian tube cancer; GC/GEJ, gastric cancer/cancers of the distal esophagus and gastroesophageal junction; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; OS, overall survival; NS, not significant; NA, not available; HR, hazard ratio; CbP, carboplatin plus paclitaxel; CG, cisplatin plus gemcitabine; GC, gemcitabine plus carboplatin.